Navigation Links
Cerecor Acquires Rights to Merck COMT Inhibitors
Date:3/20/2013

BALTIMORE, March 20, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights to develop, register and commercialize agents that inhibit catechol-O-methyltransferase inhibitors ("COMT inhibitors"), previously discovered and owned by Merck, known as MSD outside the United States and Canada. 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

COMT is an enzyme that breaks down dopamine, a neurotransmitter that plays a key role in higher brain functions such as motivation, cognition and emotion. Drugs that inhibit COMT have been used to treat patients with Parkinson's disease; however, they have poor brain penetration and limited safety and tolerability.   COMT inhibition also has broad potential applicability in other CNS diseases, such as addictive behaviors and schizophrenia, by specifically increasing dopamine levels in areas of the brain affected by these conditions.  While the development of schizophrenia drugs to date has focused on reducing psychosis, improvement in functional outcome has been largely unattainable because current drugs do not have clinically significant impact on the "negative symptoms" and cognitive impairment of the disease.  Drugs that inhibit COMT improve working memory and other measures of cognitive function in animals and in clinical studies (normal subjects and in schizophrenics). 

"Merck has developed an innovative COMT platform that has addressed the toxicity associated with existing COMT drugs.  By accessing this platform, Cerecor broadens its cognition pipeline, which also includes DAAO inhibitors.  This enhances our leadership in neuropsychiatric drug development," stated Dr. Reza Mazhari , Cerecor's VP of Drug Discovery and Development. 

Under the terms of the agreement, Cerecor will evaluate more than 2,000 molecules and select lead candidates for clinical development. Consideration includes milestone payments and royalties consistent with other preclinical licenses in neuroscience. Cerecor anticipates completing the technology transfer activities in 2013. 

"Adding COMT inhibitors to our drug development portfolio enhances our mission. Cerecor continues to focus on targets or technologies that have demonstrated human proof of concept, and for which biomarkers could be used to steer early clinical development. We are delighted that Merck has chosen Cerecor to help realize the value of such an innovative body of work as contained within their COMT patent portfolio," added Dr. Blake Paterson , Cerecor's co-founder and CEO.

"Cerecor's approach to the development of safe and effective therapies, combined with its experienced management team, makes them ideally suited to help advance this platform targeted for the treatment of CNS diseases," said Dr. Richard Hargreaves , Vice President, Worldwide Head of Basic Research, Neuroscience, Merck Research Laboratories.

About Cerecor

Cerecor Inc is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and co-founded in April 2011 by Drs. Solomon Snyder , Barbara Slusher , Blake Paterson and Mr. Isaac Blech . Cerecor is focused on translational medicine – the accelerated transfer of technology from the laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

Contact:
Karen Krumeich   
+1-410-522-8707


'/>"/>
SOURCE Cerecor Inc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerecor Announces Initiation of CLIN01-002-A
2. Dr. Magnus Persson Joins Cerecors Board of Directors
3. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
4. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
5. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
6. PLZ Aeroscience Acquires Assured Packaging
7. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
8. PneumRx, Inc. Acquires Key Assets From Broncus
9. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
10. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
11. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):